The Precision Peptide Company Inc.
BPC
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,080.65% | 298.89% | -49.50% | -96.64% | -97.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,080.65% | 298.89% | -49.50% | -96.64% | -97.29% |
| Cost of Revenue | -44.69% | -61.54% | -97.01% | -98.86% | -67.76% |
| Gross Profit | 197.67% | 136.74% | 103.53% | 99.59% | -51.41% |
| SG&A Expenses | 268.63% | 125.92% | 68.69% | -10.93% | -37.55% |
| Depreciation & Amortization | 21,900.00% | 13,100.00% | 3,511.11% | -87.50% | -62.50% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 254.68% | 118.53% | 56.73% | -18.42% | -39.56% |
| Operating Income | -246.96% | -116.37% | -58.20% | 16.26% | 33.55% |
| Income Before Tax | -464.04% | -334.56% | -61.82% | 12.23% | 33.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -464.04% | -334.56% | -61.82% | 12.23% | 33.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -464.04% | -334.56% | -61.82% | 12.23% | 33.45% |
| EBIT | -246.96% | -116.37% | -58.20% | 16.26% | 33.55% |
| EBITDA | -240.21% | -111.30% | -56.71% | 16.40% | 33.71% |
| EPS Basic | -8.76% | 4.41% | 18.10% | 38.49% | 44.38% |
| Normalized Basic EPS | 25.93% | 37.18% | 18.34% | 38.90% | 44.70% |
| EPS Diluted | -8.76% | 4.41% | 18.10% | 38.49% | 44.38% |
| Normalized Diluted EPS | 25.93% | 37.18% | 18.34% | 38.90% | 44.70% |
| Average Basic Shares Outstanding | 357.27% | 259.43% | 134.30% | 53.54% | 15.20% |
| Average Diluted Shares Outstanding | 357.27% | 259.43% | 134.30% | 53.54% | 15.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |